成人重症患者雾化治疗:不同呼吸支持模式下的雾化给药策略共识声明
该共识针对成人重症患者在接受不同呼吸支持(有创机械通气、无创通气、经鼻高流量氧疗)时雾化给药策略的争议,采用改良Delphi法,由17名国际多专业专家组成专家组,经文献检索、证据评价、3轮匿名问卷和2次在线会议达成共识。文件包含20条声明,综述了雾化药物在这些患者中的疗效与安全性证据,并为医护人员提供指导。多数推荐基于体外或实验研究(低级别证据),强调需要随机临床试验。共识旨在为真实临床场景下接受呼吸支持患者的雾化给药技术提供指导,并确定未来研究方向。
要点
- 共识涵盖有创机械通气、无创通气和经鼻高流量氧疗三种呼吸支持模式下的雾化给药技术。
- 共形成20条声明,综述雾化药物疗效与安全性证据并为医护人员提供指导。
- 多数推荐基于体外或实验研究,属低级别证据,强调需要随机临床试验。
- 17名国际多专业专家经3轮匿名问卷和2次在线会议达成共识。
适用人群与场景
- 接受呼吸支持(有创机械通气、无创通气、经鼻高流量氧疗)的成人重症患者。
处置流程与药物剂量
- 共识针对有创机械通气、无创通气及经鼻高流量氧疗三种呼吸支持模式下的雾化给药技术给出20条声明,为医护人员提供指导。
研究设计与关键结果
- 采用改良Delphi法制订共识,检索并综述文献,17名国际多专业专家组成专家组评价证据、审阅修订并投票推荐,经3轮匿名问卷和2次在线会议达成共识。
- 共识文件包含20条声明,综述雾化药物在需要呼吸支持的成人中的疗效与安全性证据,并为医护人员提供指导。
- 多数推荐基于体外或实验研究(低级别证据),强调需要随机临床试验。
证据类型、等级与局限
- 证据类型:国际多专业专家共识(改良Delphi法)。
- 多数推荐基于体外或实验研究,为低级别证据。
- 局限:多数推荐基于体外或实验研究(低级别证据),强调需要随机临床试验。
对床旁实践的改变
- 该共识为接受有创机械通气、无创通气或经鼻高流量氧疗的成人重症患者雾化给药技术提供指导,并确定未来研究方向;多数推荐基于低级别证据,强调需要随机临床试验。
指南或共识出处
- 成人重症患者雾化治疗共识声明(Ann Intensive Care)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Clinical practice of aerosol delivery in conjunction with respiratory support devices for critically ill adult patients remains a topic of controversy due to the complexity of the clinical scenarios and limited clinical evidence.
OBJECTIVES: To reach a consensus for guiding the clinical practice of aerosol delivery in patients receiving respiratory support (invasive and noninvasive) and identifying areas for future research.
METHODS: A modified Delphi method was adopted to achieve a consensus on technical aspects of aerosol delivery for adult critically ill patients receiving various forms of respiratory support, including mechanical ventilation, noninvasive ventilation, and high-flow nasal cannula. A thorough search and review of the literature were conducted, and 17 international participants with considerable research involvement and publications on aerosol therapy, comprised a multi-professional panel that evaluated the evidence, reviewed, revised, and voted on recommendations to establish this consensus.
RESULTS: We present a comprehensive document with 20 statements, reviewing the evidence, efficacy, and safety of delivering inhaled agents to adults needing respiratory support, and providing guidance for healthcare workers. Most recommendations were based on in-vitro or experimental studies (low-level evidence), emphasizing the need for randomized clinical trials. The panel reached a consensus after 3 rounds anonymous questionnaires and 2 online meetings.
CONCLUSIONS: We offer a multinational expert consensus that provides guidance on the optimal aerosol delivery techniques for patients receiving respiratory support in various real-world clinical scenarios.
参考来源
- Li J, Liu K, Lyu S, et al. Aerosol therapy in adult critically ill patients: a consensus statement regarding aerosol administration strategies during various modes of respiratory support. Ann Intensive Care. 2023. PMID: 37436585. doi:10.1186/s13613-023-01147-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。